within Pharmacolibrary.Drugs.R_RespiratorySystem.R01A_DecongestantsAndOtherNasalPreparationsForTopical.R01AX03_IpratropiumBromide;

model IpratropiumBromide
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 3.8333333333333334e-05,
    adminDuration = 600,
    adminMass = 40 / 1000000,
    adminCount = 1,
    Vd = 0.176,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.064,
    k12 = 2.3833333333333334e-05,
    k21 = 2.3833333333333334e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>IpratropiumBromide</td></tr><tr><td>ATC code:</td><td>R01AX03</td></tr><td>route:</td><td>inhalation</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>40</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>176</td><td>L</td></tr>
    <tr><td>clearance:</td><td>2.3</td><td>L/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ipratropium bromide is a short-acting anticholinergic (muscarinic antagonist) bronchodilator that is used for the management of bronchospasm associated with chronic obstructive pulmonary disease (COPD) and, to a lesser extent, asthma. It is administered via inhalation and is currently an approved medication in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers following single inhalation dose.</p><h4>References</h4><ol><li><p>Panning, CA, &amp; DeBisschop, M (2003). Tiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. <i>Pharmacotherapy</i> 23(2) 183–189. DOI:<a href=\"https://doi.org/10.1592/phco.23.2.183.32082\">10.1592/phco.23.2.183.32082</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12587807/\">https://pubmed.ncbi.nlm.nih.gov/12587807</a></p></li><li><p>MacGregor, TR, et al., &amp; Wood, CC (2016). Efficiency of Ipratropium Bromide and Albuterol Deposition in the Lung Delivered via a Soft Mist Inhaler or Chlorofluorocarbon Metered-Dose Inhaler. <i>Clinical and translational science</i> 9(2) 105–113. DOI:<a href=\"https://doi.org/10.1111/cts.12387\">10.1111/cts.12387</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26945929/\">https://pubmed.ncbi.nlm.nih.gov/26945929</a></p></li><li><p>Lee, YH, et al., &amp; Noh, GJ (2016). Efficiency of a New Mesh-Type Nebulizer (NE-SM1 NEPLUS) for Intrapulmonary Delivery of Ipratropium Bromide in Surgical Patients. <i>Basic &amp; clinical pharmacology &amp; toxicology</i> 118(4) 313–319. DOI:<a href=\"https://doi.org/10.1111/bcpt.12499\">10.1111/bcpt.12499</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26440415/\">https://pubmed.ncbi.nlm.nih.gov/26440415</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R01AX03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end IpratropiumBromide;
